+34 620 10 75 37info@nanbiosis.com

Nanbiosis

U20. Functional Validation & Preclinical Research (FVPR)

Ciber bbn

U20. Functional Validation & Preclinical Research (FVPR)

U20. logo FVPP CIBBIM-Nanomedicina Vall d'HebronVall d´Hebrón_U20,U18

Order request

Description

Located at the Valld’Hebron Research Institute (VHIR) in Barcelona, U20 In vivo Experimental Platform has three different sections, a Molecular Imaging section for in vivo, ex vivo and in vitro imaging studies (fluorescence, bioluminescence and X-rays), a preclinical animal model section and a preclinical histology section. All three sections are included within the Functional Validation & Preclinical Research (FVPR) of CIBBIM-Nanomedicine.

This unit is led by Dr. Ibane Abasolo (Head of FVPR). Its mission is to offer products and services for the preclinical proof-of-concept validation of therapeutic compounds and biomarkers with potential clinical applications. One of the distinguishing features of this unit is that basic preclinical studies including toxicology, histopathology and efficacy treatments are complemented with non-invasive optical imaging technologies. In vivo bioluminescence and fluorescence imaging allows monitoring of living mice longitudinally, offering real time insight into treatment efficacy, whole-body biodistribution and target mechanisms. Although in Spain there are other institutions with similar equipment, this is the only case in which imaging services can be combined with specifically devoted animal models.

U20. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
ICTS-2017-10-CIBER-2 Acquisition and istallation of infrastrucuture to complemnt Unis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivo Experiment Ministerio de Economía, Industria y Competitividad (MINECO) Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt) Coordinator
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated
management of Nanbiosis: Pronanbiosis II
Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant

Publications

2016

  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.
  • Pesarrodona M., Fernandez Y., Foradada L., Sanchez-Chardi A., Conchillo-Sole O., Unzueta U. et al. Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria. Biofabrication. 2016;8(2):-.
  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Cespedes M.V., Fernandez Y., Unzueta U., Mendoza R., Seras-Franzoso J., Sanchez-Chardi A. et al. Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs. Scientific Reports. 2016;6:-.

News U20

25 Nov

New Solutions to Old challenges: Key Symposium on Nanomedicine Against Cancer

Symposium on nanomedicine vs cancer: experts gather Nov 28 in Málaga to tackle tumor-targeting challenges and advance innovative therapies. Málaga, november 2024. On November 28th at 9:00 AM, the Salón de Actos at IBIMA (C/Severo Ochoa, 35, Málaga) will host the symposium “Targeting in Nanomedicine Against Cancer,” bringing together leading experts to discuss the critical challenges and advances in applying nanomedicine to oncology. Organized by IBIMA, this event will shed light on one of the most pressing issues in cancer nanomedicine: the difficulty of delivering nanostructures to tumor cells. The challenges to overcome cancer Cancer remains one of the world’s[...]

09 Oct

Nanotechnology to slow down the growth of glioblastomas

Directors of Unit 20 and Unit 3, Ibane Abasolo and Miriam Royo, show us the ReachGlio project, which uses nanomedicines to slow glioblastoma growth by targeting tumors in the brain, improving drug delivery through nanoparticles. Barcelona, october 2024. Each year, on October 9th, Nanotechnology Day is celebrated, a discipline dedicated to understanding and utilizing matter at a nanometric scale for purposes such as industrial or medical applications. Nanotechnology plays a fundamental role in many research lines developed at the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC) and the Vall d’Hebron Research Institute (VHIR). “Our goal is to propose one or more clinical trials in[...]

16 May

Temperature-sensitive hydrogels: A pioneering therapeutic approach for ovarian cancer

A new project with the participation of NANBIOSIS Unit 20 pioneers thermosensitive hydrogels for localized ovarian cancer treatment, minimizing side effects and enhancing efficacy. May 2024, VHIR/FVPR/CIBER-BBN (Barcelona). As the world recently commemorated Ovarian Cancer Day, from NANBIOSIS we proudly highlight the groundbreaking work of our collaborators in the fight against this deadly disease. Ovarian cancer stands as the seventh leading cause of cancer-related deaths, with Europe bearing the brunt of its impact, recording over 44,000 fatalities annually. In a bid to revolutionize treatment paradigms and enhance patient outcomes, researchers at the Clinical Biochemistry, Drug Delivery and Therapy (CB-DDT) Group,[...]

01 Mar

Reaching for the unreachable: New efforts to treat Lysosomal Storage Diseases

NANBIOSIS researchers pioneer novel treatments for Lysosomal Storage Diseases utilizing extracellular vesicles and liposomes, offering hope to patients. 1 March 2024, Vall d’Hebron Research Institute/ICMAB-CSIC (Barcelona) Lysosomal Storage Diseases (LSDs) encompass a group of rare disorders caused by mutations in lysosomal proteins. These mutations can lead to dysfunctional proteins responsible for breaking down cellular materials, resulting in the accumulation of deposits. Such accumulations can manifest in various neurological symptoms, ranging from progressive neurodegeneration to severe cognitive impairment. Often emerging in childhood, LSDs tragically culminate in premature death for many patients. Currently, up to 14 subtypes of LSDs can be treated[...]

27 Feb

New upcoming events: The active role of NANBIOSIS in awareness of rare diseases

For Rare Disease Day, we raise awareness through 2 events: 1 in Barcelona (Feb 28) & another in Madrid (Feb 29). Collaboration & research in focus. 28-29 February 2024, Rare Disease Day 2024 NANBIOSIS is actively involved in promoting awareness and understanding of rare diseases, Due to their lower incidence, these conditions are often face neglect in medical research and industrial treatment. To spotlight this crucial issue, NANBIOSIS is pleased to announce its participation in two significant events coinciding with Rare Disease Day celebrations. These events will address various aspects of rare and minority diseases research and treatment. Event 1:[...]

12 Feb

Polymeric Micelles Delivering Hope: A Revolutionary Strategy to Fight Cancer

NANBIOSIS researchers reach intracellular targets with encapsulated antibodies. February 2024, IQAC-CSIC/CIBER-BBN, Barcelona (Spain) and Santiago (Chile) Dr. Abasolo and her team have developed an innovative strategy to combat intracellular oncogenes, notably KRAS, implicated in various deadly cancers. By encapsulating therapeutic antibodies within polymeric micelles, they have successfully facilitated the entry of these antibodies into cancer cells, targeting internal markers. This breakthrough, achieved through international collaboration, represents a significant advancement in cancer treatment and holds promise for addressing other diseases with intracellular targets. These findings provide hope for improved therapies and outcomes in cancer and beyond. Every individual is said to[...]

16 Nov

The door is now open to a new nanoparticle-based treatment for chronic liver disease

– It is possible to achieve an administration method that improves the effectiveness and increases the safety of drugs for chronic liver disease? -Yes, with nanoparticles! – How? To find an answer, was created the european project NANOSIM (Biodegradable nanoparticles of Simvastatin as new therapeutic tool for chronic liver disease financed in the Joint Transnational Call (2018) led by the Hospital Vall d´Hebron. A translational research proposed as an approach for its use in patients. Until now, the only therapeutic option for patients is to eliminate the etiological agent (or the external promoter of damage), whether it is a virus,[...]

08 Nov

Impactful research with NANBIOSIS participation in the Poster Tour of CIBER-BBN & CIBEREHD Annual Conference.

2023 CIBER-BBN Annual meeting has taken place at Santemar Hotel, in Santander during November 6-7. This year the format of our annual conferences has been changed towards a collective event scheme between the CIBER-BBN and CIBEREHD thematic areas. On Monday 6 the scientific sessions werecommon for EHD and BBN, with appealing contents for the mixed audience. On Tuesday 7 EHD and BBN sessions will specific for each area in separate rooms (with common coffee break). Posters of both areas were on display in the exhibit hall throughout the entirety of the Annual Meeting. Moreover, at the “Posters & beers” session (Monday[...]

U20-In Vivo Experimental Unit
Read More

U21. Experimental operating rooms

JUMISC

U21. Experimental operating rooms

  • Scientific Director: Dr. Francisco M. Sánchez Margallo msanchez@ccmijesususon.com
  • Entities: Jesus Uson Minimally Invasive Surgery Centre (JUMISC)
  • Address: Carretera N-521, km 41, 10071 Cáceres
  • Phone: + 34 927 181 032
  • Web: JUMISC

Order request

Description

Experimental operating rooms with high technology and high field instrumentation to promote methodological and translational research class in Biomedicine, both minimally invasive surgery and new procedures and in preclinical development for technical evaluation, medical devices, biomaterials, etc. Surgical facilities allow the development and use of small and large animal models for research and experimental surgery in several longitudinal areas: cardiovascular diseases, liver and digestive diseases, respiratory and systemic diseases, endocrinology and urology, gynecological and reproductive diseases, pediatric diseases, orthopedics and traumatology, ophthalmology and experimental surgery in all organ systems have the infrastructure for transplant development, implants, prosthesis, biomaterials, etc. under high quality experimental conditions that allow surgery, clinical follow up and obtaining biological samples in these models.

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
MAT2016-75611-R NANOMATERIALS REGENERATIVE IN SCENARIOS OF BONE PATHOLOGY: OSTEOPOROSIS AND INFECTION AgenciaEstatal de Investigación Participant

U21. Experimental operating rooms
Read More

U22. Animal housing

JUMISC

U22. Animal housing

  • Scientific Director:  Axiel Torrescusa Bermejo atorrescusa@ccmijesususon.com
  • Entities: Jesus Uson Minimally Invasive Surgery Centre (JUMISC)
  • Address: Carretera N-521, km 41, 10071 Cáceres
  • Phone: + 34 927 181 032
  • Web: JUMISC

Order request

Description

The JUMISC Animal Housing Unit provides services to companies and research groups in many preclinical trials. This unit advises designs and conducts preclinical validation on demand. It has qualified professionals to design, monitor and validate any type of biomedical study. In addition this unit has been certified by the Spanish Agency of Medicines and Health Products (AEMPS) for studies in “Dosing of test substance and non-clinical specimen drawing” and “Biocompatibility studies of medical devices”. These two new certifications are attached to existing “in vivo toxicity”, “Tolerance” and “Pharmacodynamics”. All these certifications allow NANBIOSIS members to perform studies to verify the effectiveness, safety and biocompatibility of nanotechnology under development. A most singular fact makes this unit is the possibility of housing, maintaining and supervising large animals for preclinical validations. This Service has extensive experience in handling and care of minipigs and what it entails use in preclinical studies.

Its perimeter area is 3,200 m2, and the net floor area is 2,865 m2. It has large rooms to house the experimental animals according to their species characteristics (age, sex, weight, breed) and to the research projects they are assigned to. Among the equipment and facilities include: rooms for the maintenance of large animals, rooms for maintaining small ruminants, barrier zone for maintenance of rodents under SPF conditions, integrated operating room within the barrier area, multi-use rooms for rodents and lagomorphs maintenance, room for receipt and handling of animals, quarantine rooms pre-experimental process, room to perform small procedures and cures and preparation rooms for large animals prior to the surgical area.

This unit has facilities with a perimeter area of 3,200 m2 and it has large rooms to house the experimental animals according to their species characteristics.

Unit 22. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

U22-Animal housing
Read More

U23. Assisted Reproduction

JUMISC

U23. Assisted Reproduction

  • Scientific Director: Dr. Francisco M. Sánchez Margallo msanchez@ccmijesususon.com
  • Entities: Jesus Uson Minimally Invasive Surgery Centre (JUMISC)
  • Address:Carretera N-521, km 41, 10071 Cáceres
  • Phone: + 34 927 181 032
  • Web: JUMISC

Order request

Description

Located in the JUMISC, it has a 120 m2 laboratory, small animal surgery, clinical analysis support, etc. Features with two intracitoplasmatic micromanipulation equipment of the latest generation with IMSI, Laser and Oosight system, embryo biopsy systems, vision systems of the mitotic spindle, with flow cabinets with stereo-microscopes and heated plates, incubators with different gasses systems, equipment and cryopreservation freeze gamete and embryo, among others.

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

U23 - Assisted reproduction
Read More

U24. Medical imaging

JUMISC

U24. Medical imaging

  • Scientific Director: Dr. Verónica Crisóstomo Ayala crisosto@ccmijesususon.com
  • Entities: Jesus Uson Minimally Invasive Surgery Centre (JUMISC)
  • Address: Carretera N-521, km 41, 10071 Cáceres
  • Phone: 34 927 181 032
  • Web: JUMISC

Order request

Description

The range of medical imaging capabilities available within this Unit allow for large animal diagnostic imaging, with the possibility to integrate all the information on body organs,systems, specific diseases or animal models, etc., that can be obtained with different imaging systems,such as clinical grade Magnetic Resonance Imaging, ultrasonography CT and fluoroscopy. This Unit is highly focused on cardiovascular diseases imaging and therapy, offering a comprehensive cardiac minimally invasive service ranging from disease modeling to therapy evaluation. Regulatory requirements prior to introducing a new medical diagnostic or therapeutic technology in clinical practice determine a mandatory preclinical validation in animal models; an scenario for which this Unit is especially suited.

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

U24-Medical imaging
Read More

U25. NMR: Biomedical Applications I

Ciber bbn

U25. NMR: Biomedical Applications I

  • Scientific Director: Ana Paula Candiota AnaPaula.Candiota@uab.cat
  • Scientific Coordinator: Silvia Lope-Piedrafita Silvia.Lope@uab.cat
  • Entities: Servicio de Resonancia Magnética Nuclear (SeRMN) & Institut de Biotecnología i Biomedicina (IBB) & Universidad Autónoma de Barcelona (UAB)
  • Address: Facultad de Ciencias, Edificio C, 08193, Cerdanyola del Vallés, Barcelona, Spain
  • Phone: +34 935 814 126
  • Web: GABRMN-UAB seRMN-UAB

UAB

Order request

Description

The platform is divided between the Servei de Ressonància Magnètica Nuclear (Nuclear Magnetic Resonance Facility) (SeRMN) and the Institut de Biotecnologia i Biomedicina (IBB) for bioinformatics applications of the UAB. This platform is coordinated by Prof. Carles Arús, PI of the Nuclear Magnetic Resonance Biomedical Applications Group (GABRMN), with a recognized research track record in the use of NMR as a tool for biomedical applications, and more especifically to identify biomarkers of different pathologies. The main objective of the Platform of Biomedical Applications of Nuclear Magnetic Resonance at the Universitat Autònoma de Barcelona (UAB) is the acquisition, processing and/or interpretation of Nuclear Magnetic Resonance data.

The platform is equipped with 10 spectrometers operating at magnetic fields between 5.8 and 14.1 Teslas (T), including a MRI scanner, Bruker BioSpec, equipped with a 7T horizontal magnet for preclinical trials.

The unit also hosts a computational platform at the IBB, with a total storage capacity of 12TB, which is accessible through the UAB network. The computational platform also hosts two multicentre databases (INTERPRET and eTUMOUR), with NMR and clinical data for more than 1000 human brain tumour patients.

The uniqueness in this case lies in access, in the same location, equipment for NMR studies in vivo, ex vivo and in vitro, molecular imaging accessories by using polarization as well as fixed metabolomic patterns. This configuration allows to validate results of molecular imaging in vivo with other in vitro facilities.

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Publications

2016

  • Delgado-Goni T., Ortega-Martorell S., Ciezka M., Olier I., Candiota A.P., Julia-Sape M. et al. MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis. NMR in Biomedicine. 2016;:-.
  • Cordon-Barris L., Pascual-Guiral S., Yang S., Gimenez-Llort L., Lope-Piedrafita S., Niemeyer C. et al. Mutation of the 3-phosphoinositide-dependent protein kinase 1 (PDK1) substrate-docking site in the developing brain causes microcephaly with abnormal brain morphogenesis independently of akt, leading to impaired cognition and disruptive behaviors. Molecular and Cellular Biology. 2016;36(23):2967-2982.
  • Ferrer-Font L., Alcaraz E., Plana M., Candiota A.P., Itarte E., Arus C.. Protein Kinase CK2 Content in GL261 Mouse Glioblastoma. Pathology and Oncology Research. 2016;:-.
  • Ciezka M., Acosta M., Herranz C., Canals J.M., Pumarola M., Candiota A.P. et al. Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation. Journal of Neuro-Oncology. 2016;:1-10.

News U25

19 Dec

Leadership changes and their new contribution to cutting-edge MRI research

Prof. Ana Paula Candiota and Prof. Silvia Lope-Piedrafita lead NANBIOSIS Unit 25, advancing MRI research and glioblastoma imaging with innovative contrast agents. Barcelona, December 2024. We are proud to announce that Prof. Ana Paula Candiota has been appointed Scientific Director and Prof. Silvia Lope-Piedrafita has taken on the role of Scientific Coordinator of Unit 25 of our ICTS. This pivotal Unit specializes in NMR and MRI biomedical applications and is jointly managed by the Universitat Autònoma de Barcelona (UAB) and CIBER-BBN. Unit 25 has a longstanding reputation for excellence in magnetic resonance imaging (MRI) research, and the recent publication titled[...]

25 Sep

Latest breakthroughs in pulmonary drug delivery and cancer research at NANBIOSIS

On World Pharmacists’ Day, NANBIOSIS Units highlighted for breakthroughs in pulmonary drug delivery and cancer research, advancing treatments for respiratory diseases and brain cancer. Barcelona and Zaragoza, September 2024. On World Pharmacists Day, we celebrate the vital contributions pharmacists make, not only in patient care but also in groundbreaking research that is shaping the future of healthcare. This year 2024, we want to give this significant date a little twist: by showcasing a few examples of how our Units are contributing to healthcare and new pharmaceutical approaches. Two key NANBIOSIS units —Unit 9 and Unit 25— are at the forefront[...]

08 May

Last seat: Our Training in Spectroscopy and MRI for animal testing applications is still open.

Do not miss the chance to join our hands-on XV Workshop of Theoretical-Practical Training in MRS / MRI, with specific application in laboratory animals Our excellent teacher Dr. Silvia Lope will be at the helm in this practical workshop. And it provides all the required skills users need to operate our fantastic Biospec, available as a service in our Unit 25. The registration period for the “XV Workshop of Theoretical-Practical Training in Spectroscopy and Magnetic Resonance Imaging (MRS / MRI): Application in Laboratory Animals” is still open until May the 17th, 2024. This workshop is organized by the Department of[...]

20 Mar

Nanoparticles to modulate topography and ligand distribution at the nanoscale: impact on cell behavior

Doctor Marc Martínez from the Nanomol-Bio group – NANBIOSIS U6 from CIBER-BBN at ICMAB-CSIC, defended his PhD thesis “Nanoparticles to modulate topography and ligand distribution at the nanoscale: impact on cell behavior” on 9 March 2023 at ICMAB. he PhD thesis was supervised by Imma Ratera, Judith Guasch and Nora Ventosa from the Nanomol-Bio group at ICMAB-CSIC. Ana Paula Candiota Silveira, Scientific Coordinator of NANBIOSIS U25 was part of the Committee that evaluated the Thesis tooghether with Jesús Martínez de la Fuente, Instituto de Nanociencia y Materiales de Aragón (INMA-CSIC) (President),  and Anna Lagunas Targarona, Institut de Bioenginyeria de Catalunya (IBEC) (Vocal). As[...]

07 Sep

Philipps-Universität Marburg (Germany) -NANBIOSIS U25 collaboration on the study of tumour microenvironment (TME) changes in Glioblastoma

The scientific coordinator of NANBIOSIS U25 “RNM: Biomedical Application I”, Ana Paula Candiota, was recently awarded with a mobility fellowship from CIBER-BBN for a scientific exchange visit to Philipps-Universität Marburg, in Marburg, Germany. This scientific stage was motivated for a sustained collaboration between the research groups (GABRMN, in charge of U25 and Neurosurgery Lab group in Marburg), regarding the study of tumour microenvironment (TME) changes in Glioblastoma and possible relationship with the noninvasive MRSI-based biomarkers. Both groups have applied together to different funding calls including ERA-NET Transcan and Pathfinder Open, and Marburg group has hosted a predoctoral stage from a[...]

16 Aug

Two NANBIOSIS Units of CIBER-BBN at UAB, one of the 300 best universities in the world, according the Shanghai Ranking

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, places the Autonomous University of Barcelona among the elite of the 300 best universities in the world. This indicator organizes up to 20,000 university centers worldwide,based on transparent methodology and objective third-party data. ARWU is regarded as one of the three most influential and widely observed university rankings Two of NANBIOSIS Units created by UAB and CIBER-BBN are part of this university: U1 Protein Production Platform (PPP), led by Toni Villaverde, Neus Ferrer and Mercedes Marquez, offer an “tailored” service for the design,[...]

05 Jul

Metal-free contrast agents: novel approaches

The joint expertise of CIBER-BBN Nanomol Group – NANBIOSIS U6 from at ICMAB-CSIC (José Vidal and Vega Lloveras) and NANBIOSIS U25 at UAB (Ana Paula Candiota), led to a recently published article in the prestigious journal Biomacromolecules Brain tumours such as Glioblastomas are a challenge in the clinics and proper diagnosis and follow-up are crucial for patient outcome. Contrast agents are usually administered to patients for assessing blood brain barrier integrity and quantitation of enhancing areas are part of the clinical criteria for estimating response/relapse. However, most contrast agents currently used in clinics are based in metal elements such as[...]

10 May

Improving quality of MR spectra from mouse brain. MRSI-detected pattern in glioblastoma patients

Work performed at Unit 25 of Nanbiosis ICTS of “NMR: Biomedical ApplicationsI” is being shown at the Joint annual meeting ISMRM-ESMRMB (May 7-12th) London, with the participation of CIBER-BBN group members Ana Paula Candiota, Silvia Lope-Piedrafita, Miquel Cabañas (abstract 1), Carles Arús, Gulnur Ungan, Margarida Julià-Sapé, Alfredo Vellido and Carles Majós (abstract 2). In the first abstract, entitled “High resolution Multi-voxel spectroscopy using CSI-semi-LASER for mouse brain preclinical studies” we focused into improving quality of MR spectra obtained from mouse brain, a key factor when trying to pursue metabolomic-based biomarkers. The second abstract, entitled “MRSI-detected pattern in glioblastoma patients on[...]

U25-NMR Biomedical Applications I
Read More

U26. NMR: Biomedical Applications II

Ciber bbn

U26. NMR: Biomedical Applications II

  • Scientific Director: Prof. Ramon Martinez Máñez  rmaez@qim.upv.es
  • Scientific Coordinator: Dr. Salvador Gil salvador.gil@uv.es
  • Entities: Universitat de Valencia (UV)
  • Address: C/Dr. Moliner, 50, Edificico Investigación, 1º Pl., 46100, Valencia, Spain
  • Phone: +34 963877343
  • Tel Prof. Martínez: +34 963877343 ; Tel Dr. Gil : +34 963543135
  • Web: UV

UV

Order request

Description

Located in the Faculty of Medicine of the University of Valencia (UV) has a laboratory with a NMR (14T) for acquiring unique metabolic profiles of biofluids, cell lines and tissues. This Unit is coordinated by Dr. Ramón Martínez Máñez, PI of the Applied Molecular Chemistry Group of the Universidad Politécnica de Valencia, together with Dr. Salvador Gil, Director of the Central Service for Experimental Research (SCSIE).

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
MAT2015-64139-C4-1-R INTELLIGENT NANOMATERIALS, PROBES AND DEVICES FOR THE INTEGRATED DEVELOPMENT OF NEW TOOLS APPLIED TO THE BIOMEDICAL FIELD MINISTERIO DE ECONOMIA INDUSTRIA Y COMPETITIVIDAD Participant
MAT2015-64139-C4-C-R CHROMOGENIC AND FLUOROGENIC CHEMOSENSES FOR THE DETECTION OF NEUROTRANSMITTERS MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD Participant
PROMETEOII/2014/047 New approaches for the design of controlled release materials and the detection of dangerous compounds Generalitat Valenciana Participant
AP2012-1478 HELP CONV FPU 2012 - DE LA TORRE PAREDES, CRISTINA Ministerio de Educacion, cultura y deporte Participant
MAT2012-38429-C04-01 Development of functionalized materials with nanoscopic doors for controlled release applications and sensors for the detection of ammonium nitrate, sulfuric acid and CO Ministerio de Economia y Competitividad Participant
UPV-FE-16-A1 CONSTITUTION OF A SMART DRUG DISCOVERY PLATFORM Participant
UPV-FE-15-A2 Development of nanomaterials and sensors for early and non-invasive diagnosis and prognosis UNIVERSIDAD POLITECNICA DE VALENCIA Participant
AP2013-06017 HELP CONTRACT FPU 2013-SANCHEZ CABEZAS MInisterio de Educacion, Cultura y Deporte Participant

Publications

2016

  • Rosales A.M., Aznar E., Coll C., Garcia Mendoza R.A., Lorena Urbano Bojorge A., Gonzalez N.F. et al. Study of the dependency of the specific power absorption rate on several characteristics of the excitation magnetic signal when irradiating a SPION-containing ferrofluid. Journal of Magnetics. 2016;21(3):460-467.

News U26

17 Dec

NANBIOSIS enables new breakthrough study on Carotid Plaque vulnerability

NANBIOSIS Unit 26 identifies biomarkers of carotid plaque vulnerability, aiding stroke prevention with advanced NMR metabolomics and collaborative innovation. Valencia, december 2024. NANBIOSIS Unit 26, one of our NMR Biomedical Applications Platforms, has once again demonstrated its essential role in cutting-edge medical research. A recent study, conducted in collaboration with multiple research institutions, identified key biomarkers associated with carotid plaque vulnerability, a critical factor in stroke risk. A Collaborative Effort in Cardiovascular Research The study analyzed metabolic differences between symptomatic and asymptomatic carotid plaques, aiming to predict which plaques are at higher risk of rupture. Using advanced nuclear magnetic resonanc[...]

07 Nov

European Partnership Opens a New Era in Rare Disease Research

The European Rare Diseases Research Alliance (ERDERA) kicked off last month, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond. Paris, october 2024. The European Rare Diseases Research Alliance (ERDERA), a new initiative under Horizon Europe, has officially launched with an ambitious mission to improve the lives of 30 million people affected by rare diseases across Europe and beyond. Backed by a budget of €380 million, ERDERA brings together more than 170 organizations from the public and private sectors, led by the National Institut[...]

18 Oct

Prof. Ramón Martínez, Director of NANBIOSIS, has been awarded the Spanish National Research Prize

Prof. Ramón Martínez Máñez wins the 2024 National Research Award for his work in nanotechnology, drug delivery systems, and biomedical, environmental sensors. Valencia, october 2024. Prof. Martínez Máñez has been honored with the “Juan de la Cierva” National Research Award for the impact of his scientific career and its transfer in the field of chemistry, specifically in nanotechnology for controlled release systems and their use in sensors for medical, environmental, and agricultural applications. The evaluators also highlighted the high number of patents obtained and licensed by the awardee and emphasized the number of companies he has created, one of whic[...]

25 Oct

Ramón Martínez Máñez, Scientific Director of NANBIOSIS U26 obtains an ERC Advanced Grant

Ramón Martínez Máñez, researcher at the Polytechnic University of Valencia (UPV) and scientific director of the Bioengineering, Biomaterials and Nanomedicine area of ​​the CIBER (CIBER-BBN) and NANBIOSIS U26, has obtained an ERC Advanced Grant –the most prestigious grant from the European Research Council– endowed with 2.5 million euros for the development of the EDISON project (Engineered Particles for Chemical Communication). This project focuses on the field of chemical or molecular communication. Its objective is the study, development and application of nanoparticles that are capable of communicating with each other and whose application would represent a revolution in the field of[...]

16 Aug

The University of Valencia among the 300 best universities in the world, hosting NANBIOSIS U26 of CIBER-BBN on RNM for Biomedical Applications

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, places the University of Valencia among the elite of the 300 best universities in the world and the second of the Spanish universities. This indicator organizes up to 20,000 university centers worldwide,based on transparent methodology and objective third-party data. ARWU is regarded as one of the three most influential and widely observed university rankings The NANBIOSIS U26 NMR: Biomedical Applications II created by CIBER-BBN is hosted by the University of Valencia is led by Prof. Ramón Martínez Ma´ñez and Prof Salvador Gil Grau[...]

27 Jul

1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection

During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]

29 Mar

Is it possible to communicate microorganisms from different kingdoms? Yes, it is, using “Nanotranslators”

CIBER, March 28 2022 Researchers from the Polytechnic University of Valencia (UPV) and the CIBER-BBN has demonstrated, for the first time, the potential of using “translator” nanoparticles to facilitate communication between different types of cells or microorganisms. His study could have application in multiple fields, especially in the medical field for the prevention and treatment of cancer. “We have shown that it is possible to communicate microorganisms from different kingdoms using nanoparticles as translators. The nanoparticles process a message produced by the first type of cells (bacteria) and transform it into an understandable message for the second type of cells[...]

01 Dec

Nanomedicine in the Medicine of the Future

Scientists of CIBER-BBN and NANBIOSIS ICTS have participated in the 4th Conference “Anticipating the Medicine of the Future”, which took place on November 30th, organized by the Roche Institute Foundation. The topics for this ediction had been identified by the Observatory of Trends in the Medicine of the Future: Pharmacogenomics, Nanomedicine and Epigenomic The event counted with three roundtables for discussion in relation to the three topics. The second one, on Nanomedicine, was moderated by Joaquín Arenas, Director of the Research Institute of the 12 de Octubre University Hospital. Ramón Martínez Máñez, Professor of Inorganic Chemistry at the Interuniversity Researc[...]

U26-NMR Biomedical Applications II
Read More

U28. NanoImaging Unit

U28. NanoImaging Unit

    • Scientific Director: Dr. Mª Luisa García Martín mlgarcia@ibima.eu
    • Scientific Coordinator: Mónica Feijóo Cuaresma mfeijoo@ibima.eu
    • Entities: Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND)
    • Address: C/Severo Ochoa 35, 29590, Málaga, Spain
    • Phone: +34 952 367 600
    • Web: IBIMA-Plataforma BIONAND
Junta de Anadalucía       Universidad de Málaga
Order request

Description

The Nanoimaging Unit is located in Malaga at the Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), and it has been conceived and optimized to provide very diverse and integrated technological support for nanotechnology-based biomedical research, offering advanced services to internal and external users. This facility is coordinated by Dr Mª Luisa García Martín, who has wide expertise in the field of Magnetic Resonance Imaging and Spectroscopy applied to biomedical research.

The Unit brings together a wide range of cutting-edge technologies, and it is divided into four departments, each with a dedicated specialist:

– Small Animal Multimodal Imaging: Small animal (pre-clinical) imaging is a vital tool in biomedical research that allows biological processes and potential medicines to be studied in animal models using non-invasive methods. This department offers some of the most relevant pre-clinical imaging modalities, namely, MRI, in vivo Bioluminescence and Fluorescence Imaging, and micro-CT. These techniques are essential for preclinical evaluation and characterization of new diagnostic and therapeutic agents. The combined use of these technologies and new highly specific imaging probes are the basis of molecular imaging.

– Magnetic Resonance (NMR): it is equipped with two High-resolution NMR Spectrometers: a 400MHz NMR spectrometer for routine experiments and a higher field, 600 MHz, spectrometer dedicated to high-resolution magic angle spinning (HR-MAS) NMR and in vitro studies that are very demanding in terms of sensitivity. It also has a TD-NMR analyzer for relaxivity measurements in the clinical field (1.44 T).

– Electron Microscopy: It offers access to transmission electron microscopy (TEM), Cryo-TEM and Electron Tomography, high-resolution scanning electron microscopy (SEM) and environmental SEM. A special emphasis has been made on high-end sample preparation techniques through cryo-immobilization. All the equipment has been configured to provide its best on biological and nanomedicine applications. TEM, SEM and sample preparation facilities and services are offered to provide structural characterizations at the micro and nano scales. Biological and medical applications are the main objective of this equipment but are not limited to them. Any other scientific and engineering field can take advantage of them due to their versatility for public and private research, quality control, failure analysis, etc.

– Advanced Fluorescence: It hosts an excellent range of facilities capable of supporting high-quality biomedical research. These applications can range from the initial characterization of the fluorescent properties of novel nano-compounds to the evaluation of their medical applications using tissue culture and animal models. In addition, the range of possible applications goes far beyond nanomedicine to include the characterization of patient tissues, preclinical studies using rodent models, small-scale drug screening and studies using model organisms such as Zebrafish or Drosophila Melanogaster. The service is operated in close collaboration with the other advanced facilities of the Nanoimaging Unit, and the other units of Bionand, to ensure that researchers can easily combine fluorescence-based techniques with other complementary approaches such as Electron microscopy or Nuclear Magnetic Resonance.

Moreover, the location of the NanoImaging Unit allows it to be linked to other complementary Units available at BIONAND, such as the Cell Culture Unit (containment levels 1 and 2), the Chemical Unit (it offers a wide range of equipment and techniques in which materials and their interaction with biological samples can be characterized), the Animal House (rat, mouse and zebrafish accommodation), and the Histology Unit (it also offers Cutting/grinding based histological sectioning for hard tissues or other materials unsuitable to be sectioned by routine methods)

Services

In addition to the services within the NanoImaging Unit, the following specialised services are offered:

– Cutting/grinding based histological sectioning (Onsite&Remote) OUTSTANDING: This technique is recommended for obtaining histological samples from hard tissues or other materials unsuitable to be sectioned by routine methods, e.g. undecalcified bone tissue, metallic or ceramic implants, or samples that combine hard and soft components. With the EXAKT system, 10-15 μm slices can be made without disrupting the interface between areas of different hardnesses. Applications: Processing and fixation of fresh samples, Dehydration, plastic infiltration and polymerization, Cutting of blocks to obtain surfaces of interest, Block grinding, and Histological staining.

– Animal Housing (Onsite&Remote): The BIONAND Animal Facility Service is a research support service that aims to house experimental animals: zebrafish, rats and mice, and provide the facilities, materials, equipment and expertise needed to conduct pre-clinical trials based on the technologies and products developed in Centre from both research groups and companies

U28. Services & Rates

Active projects

TitleFundin: OrganismCall: Funding source Role
SAF2017-90810-REDIStrategic Promotion and coordinated management of Nanbiosis: Pronanbiosis IIAgencia Estatal de Investigación (AEI)Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017Partner
PICCOLO-732111Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision supportEuropean Commission-H2020H2020-ICT-2016-1Partner
0624_2IQBIONEURO_6_EPromotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseasesEuropean Union Interreg : European Territorial Co-operationPOCTEP Interreg España-PortugalPartner

Other projects

RefTitleFunding OrganismUnit Role
T96BIOMEDICAL SIGNAL INTERPRETATION & COMPUTATIONAL SIMULATIONDGAParticipant
UZCUD2016-TEC-03Optimization of a submersible device for the monitoring of the photoplestimográfica signalCUDParticipant
DPI2016-75458-RMULTI-SCALE PHYSIOLOGY-DRIVEN COMPUTATIONAL TOOLS TO ASSIST IN THE ASSESSMENT AND MANAGEMENT OF CARDIAC DYSFUNCTIONSMINECOParticipant
TIN2013-41998-RTHE AUTONOMOUS NERVOUS SYSTEM AS A MODULATOR OF CARDIAC FUNCTION: INTEGRAL RESEARCH THROUGH SIGNAL PROCESSING AND COMPUTATIONAL MODELINGMINECOParticipant

Publications

2016

  • Laguna P., Martinez Cortes J.P., Pueyo E.. Techniques for Ventricular Repolarization Instability Assessment from the ECG. Proceedings of the IEEE. 2016;104(2):392-415.
  • Pueyo E., Dangerfield C.E., Britton O.J., Virag L., Kistamas K., Szentandrassy N. et al. Experimentally-based computational investigation into beat-to-beat variability in ventricular repolarization and its response to ionic current inhibition. PLoS ONE. 2016;11(3):-.
  • Romero D., Martinez J.P., Laguna P., Pueyo E.. Ischemia detection from morphological QRS angle changes. Physiological Measurement. 2016;37(7):1004-1023.
  • Vicente J., Laguna P., Bartra A., Bailon R.. Drowsiness detection using heart rate variability. Medical and Biological Engineering and Computing. 2016;:1-11.
  • Alcaine A., De Groot N.M.S., Laguna P., Martinez J.P., Houben R.P.M.. Spatiotemporal model-based estimation of high-density atrial fibrillation activation maps. Digital Signal Processing: A Review Journal. 2016;54:64-74.
  • Bolea J., Pueyo E., Orini M., Bailon R.. Influence of heart rate in non-linear HRV indices as a sampling rate effect evaluated on supine and standing. Frontiers in Physiology. 2016;7(NOV):-.
  • Ortigosa N., Rodriguez-Lopez M., Bailon R., Sarvari S.I., Sitges M., Gratacos E. et al. Heart morphology differences induced by intrauterine growth restriction and preterm birth were measured on the ECG at preadolescent age. Journal of Electrocardiology. 2016;:-.
  • Hernando A., Lazaro J., Gil E., Arza A., Garzon J.M., Lopez-Anton R. et al. Inclusion of Respiratory Frequency Information in Heart Rate Variability Analysis for Stress Assessment. IEEE Journal of Biomedical and Health Informatics. 2016;20(4):1016-1025.
U28. NanoImaging Unit
Read More